Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma

Moleculin Biotech, Inc. today announced it has engaged contract research organization (“CRO”) Bioscience SA (“Bioscience”) to prepare for a proof-of-concept clinical trial in Poland to study its drug candidate WP1220 for the treatment of cutaneous T-cell lymphoma (“CTCL”).